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Abstract
Background:  The CBFA2T3 locus located on the human chromosome region 16q24.3 is
frequently deleted in breast tumors. CBFA2T3 gene expression levels are aberrant in breast tumor
cell lines and the CBFA2T3B isoform is a potential tumor suppressor gene. In the absence of
identified mutations to further support a role for this gene in tumorigenesis, we explored whether
the CBFA2T3B promoter region is aberrantly methylated and whether this correlates with
expression.
Results: Aberrant hypo and hypermethylation of the CBFA2T3B promoter was detected in breast
tumor cell lines and primary breast tumor samples relative to methylation index interquartile
ranges in normal breast counterpart and normal whole blood samples. A statistically significant
inverse correlation between aberrant CBFA2T3B promoter methylation and gene expression was
established.
Conclusion:  CBFA2T3B is a potential breast tumor suppressor gene affected by aberrant
promoter methylation and gene expression. The methylation levels were quantitated using a
second-round real-time methylation-specific PCR assay. The detection of both hypo and
hypermethylation is a technicality regarding the methylation methodology.
Background
Allelic loss of heterozygosity (LOH) of the human chro-
mosome 16q in several sporadic cancer types, including
breast, prostate and ovary cancers, suggests this chromo-
some arm harbors tumor suppressive loci [1-3]. The most
frequent region of allelic loss occurs within 3-megabases
(Mb) at 16q24.3 between the marker D16S498 and the
telomere [1,4]. Sequencing of the 3-Mb region has identi-
fied approximately 100 genes [4]. Eight of these have been
excluded as potential tumor suppressors for breast cancer
based on mutation analysis in tumor DNA [5]. Recently, a
messenger RNA (mRNA) expression survey was com-
pleted within 2.4-Mb of this region examining the expres-
sion profiles of over 75 genes in a panel of breast tumor
cell lines [6]. It was found that only three genes exhibited
significantly aberrant expression profiles. These genes
were highly expressed in some cell lines and lowly
expressed in others. This led to the hypothesis that this
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aberrant expression may reflect a role for these genes as
tumor suppressors in determining cancer phenotype and
behavior. One of these genes was the core-binding factor,
alpha subunit 2, translocation to 3; termed CBFA2T3.
CBFA2T3 encodes for a protein that belongs to the eight-
twenty-one (ETO) family, which also includes the genes
CBFA2T1, CBFA2T2 in mammalian cells and nervy in
Drosophila [7]. The mammalian members of this protein
family are involved in therapy-related chromosomal
translocations causing acute myeloid leukemia [8]. The
CBFA2T3 gene encodes two alternative transcripts,
CBFA2T3A (NM_005187) and CBFA2T3B (NM_175931)
(Figure 1A). CBFA2T3A reportedly functions as a nuclear
transcriptional co-repressor via its interaction with his-
tone deacetylase (HDAC) complexes [9]. CBFA2T3B func-
tions as a kinase anchorage protein in T lymphocytes and
may play a role in inflammatory response [10]. Recently,
it was demonstrated that CBFA2T3B functions as a tran-
scriptional repressor and exhibits in vitro characteristics
consistent with tumor suppressor activity [11]. This gene
was found to be lowly expressed in a number of breast
tumor cell lines and upon re-introduction it reduced their
growth on plastic and in soft agar.
Mutation analysis in breast tumor cell lines and primary
breast tumor samples failed to identify any CBFA2T3
sequence aberrations [11]. It was recognized that aberrant
promoter methylation might be the mechanism responsi-
ble for the altered expression of CBFA2T3 in breast
tumors. The expression of several tumor suppressor genes
has been found inactivated or reduced in tumors in asso-
ciation with promoter hypermethylation [12]. Promoter
hypermethylation can occur in conjunction with allelic
loss and or mutation and is regarded as an alternative
form of 'knockout' in biallelic inactivation. Accumulating
evidence now suggests that promoter hypermethylation
may affect genes that reside within regions of frequent
allelic loss more often than mutation [13]. Alternatively,
several oncogenes have been found to be over-expressed
in tumors in association with promoter hypomethylation
[14]. As such, aberrant promoter methylation is consid-
ered a fundamental process in developing cancers and has
recently received considerable interest as a rapid non-
invasive molecular screening tool for the early detection
of tumor cells in a range of bodily fluids and biopsy spec-
imens [15].
In this study, the methylation status of a high-density CpG
island promoter region located five prime to the exon 1B
sequence of the CBFA2T3B transcript is described (Figure
1A). We explored whether this region is aberrantly meth-
ylated in breast tumor cell lines and primary breast tumor
samples and whether a correlation exists between methyl-
ation and gene expression. Both aberrant hypo and hyper-
methylation levels were detected in breast tumors in
correlation with elevated and reduced expression. The
phenomenon of hypo and hypermethylation relates to
the amount of DNA used in the methylation methodol-
ogy as discussed.
Results
Isoform-specific analysis of CBFA2T3 gene expression 
levels
CBFA2T3 encodes two alternative transcripts, CBFA2T3A
and CBFA2T3B (Figure 1A). It was recently demonstrated
that CBFA2T3 expression levels are aberrant in breast
tumor cell lines. In this study, the total expression levels
were assayed using real-time RT-PCR and primers that
span exons 4–5 of the CBFA2T3 gene. The tumor suppres-
sor activity previously shown for CBFA2T3B, led us to
examine the expression profile of this transcript in breast
tumor cell lines using a TaqMan probe specific for exon
1B. CBFA2T3B displayed aberrant expression similar to
the total (Figure 2A). This aberrant expression was found
to be endogenously low in all samples examined. The
expression of this gene was so low that it could not be reli-
ably detected using Northern Blots or RNase protection
(data not shown). In addition, expression levels of the
CBFA2T3A transcript were assayed in breast tumor cell
lines using a TaqMan probe specific for exon 1A.
CBFA2T3A expressed at lower levels than CBFA2T3B, but
due to the identification of several complex splice variants
between exon 1A and exons 1B, 2, 3 and 4, further analy-
sis is required (data not shown). An example of the raw
data real-time RT-PCR expression analysis of the CBFA2T3
transcripts is shown (Additional file 1).
Qualitative analysis of CBFA2T3B promoter methylation 
levels
Based on the idea that this altered expression might
develop via aberrant methylation, the promoter activity
and methylation status of a high-density CpG island
located five prime to the exon 1B sequence of CBFA2T3B
was examined (Figures 1A and 1B). The promoter activity
was assayed using chloramphenicol acetyl-transferase
(CAT) ELISA and confirmed that a 1-kb region spanning
the island was capable of promoting a 30-fold increase in
CAT expression (Figure 2C). To determine if this pro-
moter region is aberrantly methylated in breast tumors,
24 breast tumor cell lines, 20 primary breast tumors, 20
normal breast counterparts and 24 normal whole blood
samples were screened using methylation-specific PCR
(MSP). Four separate 100–200 bp regions spanning the
promoter were amplified using primers specific for either
unmethylated or methylated cytosines at the CpG sites
shown (Figure 1B). The full results of this analysis are
summarized in Additional file 2. In general, a low 'basal'
level of methylation was detected in all samples at the var-
ious regions examined. An example of this basal methyla-Molecular Cancer 2004, 3:22 http://www.molecular-cancer.com/content/3/1/22
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tion is shown for the normal blood samples at region two
(Figure 3A). Unlike the bloods, several breast tumor cell
lines, primary breast tumors and normal breast counter-
part samples displayed complex high to low methylation
levels. An example of this complex methylation is shown
for the primary breast tumors and their normal counter-
parts at region four (Figure 3B). This analysis revealed that
only few cell lines displayed clear hypermethylation (e.g.
MDA-MB-231) or hypomethylation (e.g. BT-483) in asso-
ciation with reduced and elevated expression. To support
this association, it was found that treatment of MDA-MB-
231 cells with the demethylating agent 5-aza-2'-deoxycy-
tidine (5-Aza-dC) was capable of increasing both
CBFA2T3 and CBFA2T3B expression levels by > 100-fold
relative to controls (Figure 2B). Overall, however, it was
difficult to comprehend this complex promoter methyla-
tion and an association with expression thus suggesting
that further analysis was required.
Bisulfite sequence analysis of CBFA2T3B promoter 
methylation patterns
To understand this complex promoter methylation,
sodium bisulfite sequencing of the hypermethylated
breast tumor samples was used to examine the pattern
and frequency of methylation with this region. This anal-
ysis revealed that specific cytosines appeared more suscep-
tible to methylation compared to others (Figure 4). A
characteristic sinusoidal pattern of approximately six high
to low frequency methylation levels every 40–150 bp was
detected in cell lines and tumor samples (Figures 1C and
4). Based on this pattern, primers were designed specific
for the real-time MSP quantitation of high-frequency cyto-
sine methylation levels residing within a consensus Spe-
cificity protein (Sp1) binding site located approximately
minus 450 bp from the transcriptional start of exon 1B
(Figures 1B and 1C). As Sp1 proteins are commonly
known to regulate gene transcription, it was considered
that variable methylation at this site may be reflective of
CBFA2T3 gene structure and promoter methylation patterns Figure 1
CBFA2T3 gene structure and promoter methylation patterns. (A) CBFA2T3 encodes two alternative transcripts, 
CBFA2T3A and CBFA2T3B. CBFA2T3A is encoded by exons 1A and 2–12. CBFA2T3B is encoded by exons 1B-12 splicing out 
exon 3. Relative exon sizes are shown. The exon 1A start site contains no CpG island. The black box marks the location of a 
high-density CpG island located five prime to the exon 1B start site. The black arrowheads mark the primers used for real-time 
RT-PCR. (B) CBFA2T3B contains a CpG island of approximately 160 CpG sites spanning 1-kb of sequence. The single black 
bars represent CpG sites scaled relative to each other. CAT ELISA promoter constructs and primers used for MSP, real-time 
MSP and bisulfite sequencing are shown. The asterisk marks the location of the amplicon and internal primers used for second-
round real-time MSP. (C) CBFA2T3B promoter methylation patterns were examined in hypermethylated cell lines using 
sodium bisulfite sequencing. A characteristic sinusoidal pattern of approximately six high to low frequency methylation levels 
every 40–150 bp was detected. The high-frequency cytosine methylation levels residing within a consensus Sp1 binding site 
located approximately minus 450 bp from the transcriptional start of exon 1B are shown.
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elevated or reduced expression and thus suitable for
resolving and correlating the complex promoter methyla-
tion levels.
Quantitative analysis of CBFA2T3B promoter methylation 
levels
To assay CBFA2T3B promoter methylation levels at this
Sp1 site, a bisulfite sequencing amplicon spanning this
region was initially PCR amplified and column purified
from 24 breast tumor cell lines, 55 primary breast tumors,
22 normal breast counterparts and 46 normal whole
blood samples. Second-round real-time MSP was per-
formed on the amplicons using internal forward primers
to detect for either unmethylated or methylated cytosines
at the Sp1 site. Standard curve dilutions of previously pre-
pared internally primed clones representative of either
unmethylated or methylated sequence were used to
extrapolate methylation levels and normalize for differ-
CBFA2T3 gene expression levels, 5-Aza-dC re-expression and promoter activity Figure 2
CBFA2T3 gene expression levels, 5-Aza-dC re-expression and promoter activity. (A) CBFA2T3 gene expression 
levels were assayed using real-time RT-PCR. Several breast tumor cell line and normal tissue sample expression levels are 
shown. The y-axis represents mRNA mlcls expressed per 104 cells shown on a log scale (mean ± SD, n = 6). Fold changes in 
expression relative to normal breast expression are shown above each sample. The white diamonds and white squares repre-
sent expression levels of the housekeeping genes cyclophilin A (CYPA) and ATPase coupling factor 6 subunit (ATP5A), respec-
tively. CBFA2T3B and CBFA2T3 expressed at endogenously low yet aberrant levels in breast tumor cell lines. Using normal 
breast as a reference, CBFA2T3B (600 mRNA mlcls per 104 cells) and CBFA2T3 (1,800) were low compared to ATP5A 
(600,000) and CYPA (1,600,000). CBFA2T3 expression ranged 30,000-fold from 4 to 120,000 mRNA mlcls per 104cells in 
MDA-MB-231 and BT-483, respectively. In contrast, CYPA and ATP5A expression ranged 2-fold and 20-fold, respectively 
(100–200 and 15–300 mRNA mlcls per cell). Expression levels were also examined in several primary breast tumor samples for 
which total RNA was available (see Figure 6). (B) CBFA2T3 re-expression levels were examined in MDA-MB-231 cells using 5-
Aza-dC. Fold changes in CBFA2T3B, CBFA2T3 and SYK expression levels are shown upon exposure to 5-Aza-dC relative to 
control untreated cells. > 100-fold re-expression was detected in CBFA2T3 and CBFA2T3B. 5-Aza-dC had no affect on 
CBFA2T3A expression (data not shown). > 1,000-fold re-expression was also detected in SYK, a control gene known to be 
hypermethylated and down-regulated in MDA-MB-231 cells. (C) CBFA2T3B promoter activity was assayed using CAT ELISA. 
Promoter constructs labeled A to D (see Figure 1B) were inserted upstream of the CAT reporter in pBLCAT3 (Boehringer 
Mannheim). pBLCAT2 driven by the tyrosine kinase promoter was used as a positive control. 2.0 × 106 293T cells were trans-
fected in triplicate using Lipofectamine 2000 (Invitrogen) with 1.5 µg of construct and control vector and 0.3 µg of the internal 
pSVβ-galactosidase control vector (Stratagene). Cells were lysed after 24 h and CAT concentrations determined using ELISA. 
Of the four constructs labeled A to D, the 1-kb B construct promoted a 30-fold increase in CAT expression (mean ± SD are 
triplicates, n = 3).
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ences in amplification efficiencies. The methylated
cytosines were expressed as a fractional ratio of unmethyl-
ated cytosines to determine the methylation indices [mi =
m/(m + u)]. On plotting the indices, a clear difference
between the tumor, normal groups and complex pro-
moter methylation levels was revealed (Figure 5). The nor-
mal blood samples maintained a specific basal
methylation level and were similar to normal breast coun-
terparts with methylation indices ranging from 0.006–
0.09 and 0.002–0.08, respectively. Median methylation
index levels were 0.02 in normal bloods and 0.01 in nor-
mal breast counterparts. In contrast, several breast tumor
cell lines and primary breast tumors were highly variable
relative to the normal samples with methylation indices
ranging from 0.0002–0.8 and 0.0001–0.9, respectively. A
Levene's test revealed a statistically significance difference
in variances of methylation indices with the tumor groups
being more varied than the normals (P = .001). It was pre-
dicted that 83–75% of breast tumor cell lines and 78–
69% of primary breast tumors displayed aberrant methyl-
ation levels outside the methylation index interquartile
ranges of the normal blood (0.02–0.04) and normal
breast counterpart samples (0.008–0.03), respectively.
Half of the aberrations detected in breast tumor cell lines
were either hypo or hypermethylated relative to the nor-
mal breast counterpart interquartile ranges. Up to 22% of
the primary breast tumors were hypomethylated and 47%
hypermethylated relative to the normal breast counterpart
interquartile ranges. An example of the raw data real-time
MSP and melt curve analysis showing the aberrant meth-
ylation levels in breast tumor cell lines compared to nor-
mal whole blood samples is shown (Additional files 3 and
4).
Correlation of CBFA2T3B promoter methylation and gene 
expression levels
To correlate CBFA2T3B promoter methylation levels with
gene expression, the methylation indices from 24 breast
tumor cell lines and 20 primary breast tumor samples
were plotted against their expression. A statistically signif-
icant inverse correlation between CBFA2T3B promoter
methylation and exon 1B specific expression was estab-
lished (r2 = 0.63; r = -0.8, P = .0002). Based on the possi-
bility that five prime RNA degradation and secondary
structures may have affected the exon 1B complementary
DNA (cDNA) synthesis, a correlation between methyla-
tion and the total expression is alternatively shown (Fig-
ure 6). CBFA2T3B promoter hypermethylation and
reduced expression inversely correlated with hypomethyl-
ation and elevated expression (r2 = 0.72; r = -0.9, P <
.0001). At a hypermethylated index of around 0.9,
approximately 4 mRNA molecules (mlcls) per 104 cells
were detected compared to a hypomethylated index of
0.0001 and 120,000 mRNA mlcls per 104  cells. The
number of CBFA2T3B promoter mlcls methylated per cell
for each breast tumor cell line was also calculated by mul-
tiplying the methylation index values by the number of
16q24.3 DNA mlcls per cell as previously determined by
FISH [16]. These values were plotted against expression in
aim to improve the original correlation (r2 = 0.77; r = -0.9,
P < .0001) (Additional file 5). By plotting these data sets
a power regression was derived which could be used to
solve unknown x or y values.
Discussion
In this study, it has been demonstrated that expression of
the CBFA2T3B isoform is altered in breast tumors and that
this correlates strongly with aberrant CpG island pro-
CBFA2T3B promoter methylation levels examined using MSP Figure 3
CBFA2T3B promoter methylation levels examined 
using MSP. The full results of this analysis in breast tumor 
cell lines, primary breast tumors, normal breast counterparts 
and normal whole blood samples are summarized in Addi-
tional file 2. (A) An example of the characteristic basal meth-
ylation levels detected in all samples is shown for normal 
blood samples examined at region 2. (B) An example of the 
complex high to low methylation levels is shown for 20 pri-
mary breast tumor samples with adjacent normal breast 
counterparts. The pUC19 DNA/MspI marker concentrations 
reflect an approximate concentration of 100 to 1 unmethyl-
ated to methylated mlcls. The asterisks indicate the samples 
examined by bisulfite sequencing.
Primary breast tumor/normals- region 4 unmethylated
B Primary breast tumor/normals- region 4 methylated
A  Normal whole blood- region 2
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moter methylation. Moreover, a comprehensive method
for the detection, quantitation and correlation of pro-
moter methylation and gene expression levels has been
developed. MSP was used in combination with sodium
bisulfite sequencing to identify sites within the CBFA2T3B
promoter region displaying high-frequency methylation
in breast tumors. Second-round real-time MSP was used
to quantitate methylation levels at these sites in breast
tumor cell lines, primary breast tumors, normal breast
counterparts and normal whole blood samples. The
CBFA2T3B promoter methylation levels were calculated
as methylation indices and the indices from breast tumors
were plotted against their expression.
Validated methylation detection using the MSP and real-
time MSP methods
Throughout the development of this method, it was rec-
ognized that a pre-requisite for valid MSP amplification
required that sufficient amounts of bisulfite modified
DNA were used in order to detect methylation and avoid
stochastic effects when quantitating low target mlcl num-
bers and parameters relating to particle distribution statis-
tics. The amount of DNA modified and subsequently
amplified is an important parameter in terms of actually
detecting potential CpG methylation in a given specimen
as discussed.
Most MSP studies use 50 ng of bisulfite modified DNA for
amplification. As a normal diploid cell contains an
average 6.6 ρg of DNA, this equates that approximately
15,000 alleles or mlcls are made available as starting tem-
plates for MSP. If for example, 1 mlcl in 1,000 of these is
methylated (mi = 0.001) for a given gene at a specific CpG
site(s), then approximately 15 mlcls will act as potential
starting templates. Routinely, in unmodified DNA speci-
mens a 'purified' 100–300 bp amplicon diluted to this
mlcl number should be detected at around 28–30 cycles
of real-time PCR under standard primer efficiencies. Ini-
CBFA2T3B promoter methylation patterns examined using bisulfite sequencing Figure 4
CBFA2T3B promoter methylation patterns examined using bisulfite sequencing. The methylation patterns in 
breast tumor cell lines, primary breast tumors, normal breast counterparts and normal whole blood samples are shown. The y-
axis represents protected 5-methylcytosines scored as percent cytosines methylated per 5–10 clones. The complete methyla-
tion maps displaying 160 CpG sites spanning 1-kb of sequence are shown for breast tumor cell lines only. The white bars indi-
cate the Sp1 sites targeted by second-round real-time MSP. Bisulfite sequencing of the CBFA2T3B promoter region in 
hypermethylated breast tumor samples MDA-MB-231, MDA-MB-468 and 14T revealed a characteristic sinusoidal methylation 
pattern. This sinusoidal pattern was also detected in samples SK-BR-3, 14N and 17T at levels approximately 1 tenth of the 
hypermethylated samples. No methylation was detected in the normal blood samples 4B and 5B or the breast tumor samples 
3T and MCF-7.
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tially, this is a late cycle threshold (CT) for the detection of
amplification and is prone to stochastic effects. Under
MSP conditions, the DNA has been bisulfite modified
which introduces numerous variables that further reduce
the overall probability of detection. Upon modification
multiple sequence permutations at the CpG site(s) of
interest may arise (e.g. from 3 CpG sites a total 8 possible
C to TpG permutations exist as 23 = 8). If primers are
designed to detect a permutation present at say 4 mlcls in
the above example of 15 mlcls (i.e. at attogram starting
amounts), then under MSP, a 100–300 bp amplicon at
this mlcl number will not amplify until after 35 cycles or
may not amplify at all. Moreover, because the initial cycles
of MSP are asymmetric the starting template mlcl num-
bers are further reduced. In addition, it is well known that
the DNA is substantially degraded following bisulfite
modification with studies demonstrating up to 84–96%
degradation [17]. If 1 µg of DNA is modified, as routinely
CBFA2T3B promoter methylation levels assayed using second-round real-time MSP Figure 5
CBFA2T3B promoter methylation levels assayed using second-round real-time MSP. The methylation levels in 
normal whole blood samples (nwb), normal breast counterparts (nbc), primary breast tumors (pbt) and breast tumor cell lines 
(btcl) were assayed at the Sp1 site shown in Figure 1C using real-time MSP. The y-axis represents methylation levels plotted as 
methylation indices [mi = m/(m + u)] on a log scale. Each white circle represents a different sample. The breast tumor cell lines 
examined are shown in descending order from high to low methylation. The horizontal bars mark the median methylation indi-
ces calculated for each group. The asterisks mark the interquartile ranges for normal groups. The median methylation indices 
and (interquartile ranges) were 0.02 (0.02–0.04) for nwb, 0.01 (0.008–0.03) for nbc, 0.03 (0.009–0.08) for pbt and 0.02 (0.002–
0.3) for btcl. The median methylation index variance in each tumor group was statistically significantly different than the normal 
groups (P = .001); nwb/btcl (P < .0001), nwb/pbt (P = .009), nbc/btcl (P = .01), nbc/pbt (P = .05). The normal group median 
methylation index variances were not significantly different; nwb/nbc (P = 0.6).
 
 
M
e
t
h
y
l
a
t
i
o
n
 
i
n
d
e
x
 
0.0001
0.001
0.01
0.1
1.0
BT20
BT474
BT483
BT549
CAMA1
DU4475
HBL100
HS578T
MB134
MB157
MB175
MB231
MB361
T47D
MB415
MB436
MB453
MB468
MCF12A
MCF7
SKBR3
UACC893
ZR7530
ZR751
nb
n = 46 n = 21
nbc
n = 55
pbt 
n = 24
btcl
*
*
*
*Molecular Cancer 2004, 3:22 http://www.molecular-cancer.com/content/3/1/22
Page 8 of 16
(page number not for citation purposes)
reported, and say 80% is degraded, then based on an
unlikely recovery rate of 100%, only 20% of the original
pool of templates used in the 50 ng will be available for
amplification. Thus, in the above example if only 20% of
the 15 mlcls and its possible permutations are available
then they may not amplify at all. The pool of primer spe-
cific methylated templates could in fact be instantly
diminished. When considering the levels of bisulfite-
mediated degradation in 1 µg of DNA, even alleles meth-
ylated at levels as high as 1 in 10 might be difficult to
detect or become spurious. For instance, if assuming that
a 100 times more template is available (i.e. 1,500 mlcls)
yet permutations exist (i.e. 400 mlcls) and the recover rate
is only 4%, then as little as 16 mlcls will be available as
starting templates for amplification.
CBFA2T3B promoter methylation levels versus gene expression Figure 6
CBFA2T3B promoter methylation levels versus gene expression. The data for 24 breast tumor cell lines and 20 pri-
mary breast tumor samples are shown. The y-axis represents methylation levels assayed using real-time MSP and plotted as 
methylation indices [mi = m/(m + u)] on a log scale. The x-axis represents total expression levels assayed using real-time RT-
PCR and plotted as mRNA mlcls per 104 cells on a log scale. Each white circle represents a different primary breast tumor sam-
ple and the black circles represent the breast tumor cell lines. The breast tumor cell lines examined are shown in descending 
order from high to low methylation. A statistically significant inverse correlation was established between promoter hyper-
methylation (mi = 0.9) and reduced expression (4 mRNA mlcls per 104 cells) versus hypomethylation (0.0001) and elevated 
expression (120,000) (r2 = 0.72; r = -0.9, P < .0001). A power regression (y = cxb) describes the relationship between methyl-
ation and expression.
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Thus, several technical thresholds exist for the detection of
methylation using MSP. The use of 1 µg of DNA for mod-
ification, 50 ng for amplification, sequence permutations,
PCR efficiency and bisulfite-mediated DNA degradation
all reduce the overall probability and validity of detection.
To warrant potential detection of methylation in a given
specimen at specific CpG sites above a threshold of say 1
in 1,000, it was found necessary to use at least 10X cover-
age of the 1 µg amount or 10 µg of DNA for modification
and 400–500 ng for MSP amplification. Taking into
account the above example, this should provide that at
least 30–40 mlcls are made available as starting templates,
which should amplify within 28 cycles. Specimens with
methylation levels lower than this, such as 1 in 50,000,
will not be reliably detected and require the use of second-
round nested MSP amplification. In this case, the first-
round will still require sufficient amounts as any initial
stochastic effects may result in poor reproducibility for the
second-round. Moreover, as demonstrated in this study,
bisulfite sequence analysis of the CBFA2T3B promoter
methylation patterns in the hypermethylated MSP sam-
ples indicated that the potential for variable methylation
frequencies do exist. In this case, it was found that even
with sufficient amounts of DNA the qualitative MSP was
unreliable and presented complex methylation data. The
use of MSP primers for sites that are not methylated or
methylated at low to high frequencies, in combination
with these other technical thresholds, created complex
stochastic methylation data merely decipherable by exam-
ining several regions. As a result, this concealed the true
methylation status in a majority of the samples under
investigation. Only those samples with clear hypermeth-
ylation (e.g. MDA-MB-231) or hypomethylation (e.g. BT-
483) were greatly reproducible and associated with
reduced and elevated expression (Figure 2A and Addi-
tional file 2).
To overcome these technical thresholds, a second-round
real-time MSP assay was developed. A sequencing ampli-
con displaying high-frequency methylation sites was
initially PCR amplified under 10X coverage conditions
and column purified from all samples. Second-round
real-time MSP was performed on approximately 100 ρg of
the amplicon using internal forward primers to detect for
either unmethylated or methylated cytosines at the high-
frequency sites. Using this approach, methylation was
detectable in every sample examined. All samples ampli-
fied with 28 cycles and a methylation index was calculated
for these. In comparison, when the standard MSP condi-
tions were assayed by real-time using SYBR Green I, it was
found that the CT of methylation detection was below 28
cycles for most samples (data not shown). Extremely low
methylation levels, such as those in BT-483, were undetec-
table using this method but were detected using the sec-
ond-round. In the latter case, up to 1 methylated mlcl in
10,000 (mi = 0.0001) could be reliably detected within 25
cycles of amplification (Figure 5 and Additional file 3).
Notably, no wild-type, unmethylated or methylated cross-
amplification was detected when using more DNA. If this
occurs then there may be a problem with primer design or
modification as the conversion should be complete. In
fact, with more DNA a bias in amplification for the target
sequence should be created.
In addition, several other technicalities were overcome.
The use of only a single second-round primer to quanti-
tate the methylation levels of the high-frequency sites
limited the number of possible 5-methyl-CpG sequence
permutations that could perturb the accuracy of quantita-
tion. This coupled with the quantitation of methylation
levels from absolute standard curves enabled the normal-
ization of reaction efficiencies and calculation of absolute
methylation indices [mi = m/(m + u)] and absolute meth-
ylation ratios (u/m). The methylation ratios are simply an
alternative way of expressing the methylation data (Addi-
tional file 6). The calculation of these single methylation
values based on the quantitative normalization
discriminates against biased amplifications and compari-
sons of unmethylated to methylated 'band' intensities
when using MSP. Moreover, the absolute quantitation of
indices and ratios offers improvement over the relative
methods, such as comparative cycle thresholds (∆∆CT), as
they have biological significance, are less consuming,
more accurate, and do not require the dynamic range in
amplification efficiencies of target and references to be
similar to enable valid quantitation.
The concept of gene promoter hypo and hypermethylation
Thus, by using this method it was possible to detect
CBFA2T3B promoter methylation in all samples. This
phenomenon may actually be widespread for genes under
the control of methylation as in accordance with the
replication model of maintenance methylation [18-20].
This model might suggest that the CpG island is not just
randomly methylated; the CpG island is 'always' methyl-
ated by memory yet propagated at variable levels for cell
type-specific expression or at aberrant levels in association
with cancers. Remarkably, in this study it was found that
the methylated CBFA2T3B CpG island is propagated as a
sinusoidal pattern at aberrant levels in both permanent
cell lines and recently resected tumor specimens suggest-
ing that a methylation memory does exist. In fact, it was
recognized that the bisulfite sequencing detection levels
of this sinusoidal pattern complemented the second real-
time MSP quantitations. For example, a methylation ratio
in SK-BR-3 of 10:1 (mi = 0.1) was concordant with a 1 in
10 or 10% 5-methylcytosine per 10 clone frequency (Fig-
ure 4 and Additional file 6). If by comparing the other
bisulfite sequencing levels with their methylation ratios
this might suggest that up to 30, 60, 90 or 5,000 clones ofMolecular Cancer 2004, 3:22 http://www.molecular-cancer.com/content/3/1/22
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4B, 5B, 3T and MCF-7, respectively, would require
sequencing in order to detect 1 methylated sinusoidal
mlcl.
Based on the idea that promoter methylation may occur
ubiquitously, the concept arises; what is hypo and hyper-
methylation. In this study, it was demonstrated that hypo
and hypermethylation are merely a prediction of levels
outside a majority or 'interquartile range' of methylation
levels found in the normal samples. For instance, of all the
methylation levels detected in the cell lines, only 37.5% of
these were predicted as either hypo or hypermethylated
relative to the interquartile ranges of normal breast meth-
ylation. Moreover, the number of predicted hypo and
hypermethylated samples are much lower when com-
pared to the 'full range' of normal methylation ratios as
shown in Additional file 6. This is considerably lower for
the primary breast tumor samples (i.e. only 24% hyper-
methylated relative to normal breast) and is likely due to
the heterogeneity of breast tumors in concealing the true
tumor-related methylation levels. Regardless, by using a
more sensitive detection method, the phenomenon of
hypo and hypermethylation has appeared.
The phenomenon hypomethylation is a reflection of the
low methylation levels that can be detected in the
'hypomethylated' samples relative to the methylated and
hypermethylated samples. Alternatively, the phenome-
non of hypermethylation is readily observed yet indicates
that the detection of methylation alone does not simply
represent hypermethylation. The CBFA2T3B gene is meth-
ylated in all samples and according to MSP in a high-per-
centage of samples. In effect, several studies which have
examined the methylation status of potential tumor sup-
pressors and cancer-related genes often demonstrate
methylation in a high-percentage of samples and state
hypermethylation based on the detection of methylation.
Examples include, ras-effector nore1A (RASSF1A) [21,22],
stratifin (14-3-3σ) [23], p15 and p16 [24], O6-methylgua-
nine-DNA methyltransferase (MGMT) [25], mismatch
repair gene (hMLH1) [26] and hyperplastic colon polyps
gene (HPP1) [27]. In these cases, as with CBFA2T3B, it is
probable that only a small percentage of this methylation
has cancerous significance in terms of 'methylation-
induced silencing', which is routinely confirmed by corre-
lation with 'absence' of expression. Notably, several stud-
ies use insufficient amounts of RNA and cDNA for
expression analysis and state the absence of amplification
to represent inactivation rather than a level of reduction,
particularly in cases of low endogenous expression. The
need for quantitation to classify methylation levels has
been recognized for genes such as glutathione S-trans-
ferase P1 (GSTP1) [28] and adenomatous polyposis coli
(APC) [29], although in these cases the use of low DNA
may nevertheless affect intra and interassay
reproducibility.
In biological terms, several scenarios exist as to how these
aberrant methylation levels might develop. In the case of
hypomethylation, a correlation could be made with
severely duplicated chromosome copies of 16q24.3 (e.g.
BT-483, MCF-7). A possible scenario here is that the
hypomethylation is apparent because of a duplicated
copy number and thus, for example, not a direct cause of
reduced DNA methyltransferase activity or over-expres-
sion per se. In the case of hypermethylation, a correlation
could be made with 16q24.3 LOH (e.g. MDA-MB-231,
MDA-MB-468). An emerging scenario here is that the
hypomethylation induces 16q LOH to promote aberrant
DNA methyltransferase activity and hypermethylation
[13]. Accumulating evidence suggests that the hypermeth-
ylation itself, or 'aberrant' methylation, may be targeted to
constantly methylated CpG islands (i.e. methylation
induces methylation), and in addition targeted to tran-
scriptionally inert CpG islands [19]. In this study, it was
found that the CBFA2T3B promoter region is in fact
constantly methylated at a median methylation index of
0.02 (i.e. 2 mlcls in 100 are methylated). When compar-
ing this median methylation index with a median gene
expression index from the breast tumor cell lines, it was
calculated that only approximately 20 mRNA mlcls per 98
'active' alleles are transcribed. These calculations are
shown in Additional file 5. This suggests that the
CBFA2T3B gene is not only constantly methylated but
also largely transcriptionally inert with the remaining
active alleles possibly trans-factor dependent for
expression.
Although the nature of such targeted aberrations are
unknown, several studies demonstrating that altered
maintenance and or de novo DNA methyltransferase
activities can induce tumorigenesis, clearly demonstrates
that the controlled methylation of CpG islands is crucial
for normal cell development [30-34]. Accordingly, an in
silico prediction of several Sp1, homeotic, epidermal and
insulin growth factor recognition sites within the
CBFA2T3B promoter region may implicate a role for this
element in epithelial development. How the CBFA2T3B
CpG island is maintained and dispersed at specified levels
within a population of cells is unknown but likely relates
to the methylation machinery in controlling distribution
within a cell type-specific population (i.e. methylation
memory and or phenotype). In this study, it was shown
that aberrant deviations outside these specified levels
occur profoundly in a majority of breast tumors, particu-
larly the pure tumorigenic cell lines, and as such might
comprise an element in tumor formation.Molecular Cancer 2004, 3:22 http://www.molecular-cancer.com/content/3/1/22
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Conclusions
Overall, this study lends further support to the idea that
CBFA2T3B is aberrantly regulated in breast cancer. Addi-
tional clues supporting a role for this gene in tumor sup-
pression may reside within its protein structure.
CBFA2T3B contains a characteristic zinc finger myeloid-
nervy-DEAF-1 (zf-MYND) domain and nervy homology
regions [7]. Several studies demonstrate that these regions
function in transcriptional co-repression via interaction
with HDAC and or nuclear co-repressor complexes [9,35-
38]. Accumulating evidence suggests the zf-MYND
domain, which is also common to developmental pro-
teins RP-8, DEAF-1, suppressin, Blu, BS69, PDCD2 and
Bop, may interact with co-repression complexes to regu-
late cell-cycle transcription during cell type-specific differ-
entiation [39-46]. Abnormal regulation may be central to
tumor formation as supported by reports that several zf-
MYND-like proteins display tumor suppressive activity.
Recently, much emphasis has been placed on the develop-
ment of methylation-based tumor biomarkers for early
breast cancer detection to predict disease outcome and
strategies for therapy [15]. Interesting data indicates that
the use of nipple aspirate fluids may provide for a rapid
non-invasive source of screening material for methylation
biomarker analysis [47]. Similar studies are underway to
evaluate if the methylation status of CBFA2T3B presents
biomarker utility. Although in this case, because the nor-
mal breast fluids and breast tumors themselves are histo-
logically complex tissues containing a variety of cell types,
it is recognized that further studies are required to refine
the methylation index interquartile ranges. This may
involve large-scale comparisons between normal and
tumor cells captured using laser microdissection. Ideally,
such normal controls would be resected at autopsy or
reduction mammoplasty from non-risk category
individuals.
Methods
Sample collection and nucleic acid isolation
24 breast tumor cell lines were obtained from the Ameri-
can Type Culture Collection and cultured under
recommended conditions. 46 normal whole blood sam-
ples, 55 primary breast tumor samples with pathologically
classified grade III lesions and 22 adjacent normal breast
counterparts samples were obtained with clinical research
approval from the Flinders Medical Centre, Department
of Surgery. Breast tumor cell line, primary breast tumor
and normal breast counterpart genomic DNA was isolated
using GenElute for Mammalian Tissues (Sigma). Whole
blood genomic DNA was isolated using the QIAamp DNA
Blood Kit (Qiagen). Breast tumor cell line and primary
breast tumor total RNA was isolated using RNAqueous-
4PCR (Ambion). Nucleic acid concentrations were deter-
mined using RiboGreen (Molecular Probes). Breast tumor
cell line, primary breast tumor and normal tissue (Clon-
tech) total RNA extracts were DNase I treated (Ambion).
Real-time reverse transcription-PCR (RT-PCR)
10–20 µg of total RNA was oligo(dT)16 reverse transcribed
at 55°C for 2 h using MMLV (Promega) with addition of
RNAguard (Promega) and 5% DMSO. CBFA2T3, CYPA,
ATP5A and SYK expression levels were assayed by real-
time RT-PCR using SYBR Green I (BMA). CBFA2T3 iso-
form expression levels were assayed using TaqMan probes
specific for exons 1A and 1B (GeneWorks). Real-time RT-
PCR was performed on a Rotor-Gene 2000 (Corbett
Research) using standard 25 µl HotStar Taq conditions
(Qiagen) on cDNA equivalent to 100–1,500 ng total RNA.
0.35X final SYBR Green I or 200 nM probe was used for
detection. Amplifications were at 95°C for 10 min, 45
cycles at 94°C for 20 s, annealing temperature for 30 s and
72°C for 30 s. Primer sequences and annealing tempera-
tures are shown (Additional file 7). Unknown expression
levels were extrapolated from standard curve dilutions of
column purified cDNA amplicons. Replicate standard
curve assays (n ≥ 2) were used with CT coefficient varia-
tions averaging < 15% over six orders within replicates
and between dilutions. mRNA mlcl numbers were quanti-
tated from samples at the parameter CT from standard
curves with known mlcls/µl calculated from the dilution
mass in µg/µl ÷ M.W. of ssRNA transcript (× 6.02 × 1017
mlcls/µmole). mRNA mlcls per cell were calculated at the
CT concentration ÷ amount of total RNA (ρg) per reaction
multiplied by 4 based on a 4 ρg total RNA per cell estima-
tion. mRNA was shown as raw expression data (n > 4) and
or normalized against CYPA or ATP5A. Several other
housekeeping and cancer-related gene expression levels
were quantitated to ensure the mRNA mlcl per cell estima-
tions were compatible with other methods (data not
shown).
Sodium bisulfite modification
10–20  µg of genomic DNA was digested overnight at
37°C with restriction enzymes XbaI, XhoI, HindIII and
EcoRI and cleaned using nucleotide purification columns
(QIAvac 24, Qiagen). The digested DNA was pooled and
bisulfite modified [17]. 10 µg of DNA was diluted in 500
µl of water and denatured with 55 µl of 2 M NaOH for 20
min at 37°C. DNA was mixed with 300 µl of 10 mM hyd-
roquinone (Sigma), 5.2 ml of 3.6 M NaHSO3 (pH 5.0)
(Sigma), overlaid with paraffin oil and deaminated in the
dark for 16 h at 55°C. DNA was desalted using Qiagen
purification columns, eluted in 500 µl water and desul-
fonated with 55 µl of 3 M NaOH for 20 min at 37°C. DNA
was neutralized and precipitated with 800 µl of 10 M
ammonium acetate (pH 7.0), 20 µl linear acrylamide and
5 ml cold 100% EtOH. Modified DNA was pelleted, resus-
pended in 40 µl 1 mM Tris-Cl (pH 8.0) and the concen-
trate stored at -80°C.Molecular Cancer 2004, 3:22 http://www.molecular-cancer.com/content/3/1/22
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Methylation-specific PCR (MSP) and sodium bisulfite 
sequencing
Four 100–200 bp regions spanning approximately 1-kb of
the CBFA2T3B promoter region were amplified from ≥
300 ng of bisulfite modified DNA under standard HotStar
Taq conditions using primers specific for either unmethyl-
ated or methylated cytosines. Hypermethylated breast
tumor samples were used for bisulfite sequencing to gen-
erate a CBFA2T3B promoter region methylation map.
Four 300–400 bp regions spanning the promoter were
amplified under standard conditions as described above
using primers simultaneous for both unmethylated and
methylated cytosines. The amplicons were sub-cloned
into pGEM (Promega) and 5 to 10 clones sequenced using
BigDye (Applied Biosystems). Primer sequences and
annealing temperatures are shown (Additional file 7).
Demethylation assay
MDA-MB-231 was treated with the demethylating agent
5-Aza-dC (Sigma). Approximately 2.0 × 105 cells per T75
flask were seeded in 10 ml RPMI-1640 supplemented with
10% FCS, 15 mM HEPES, 10 mg/liter PGS and cultured
for 48 h at 37°C with 5% CO2. Cells were treated with 50
µm 5-Aza-dC for 120 h and replenished with fresh
medium and 5-Aza-dC every 24 h. These concentrations
are not inhibitory to cell growth [48]. Concentrations
ranging from 1–5 µM 5-Aza-dC had no affect on expres-
sion levels (data not shown). Control untreated cells were
cultured in parallel and supplemented with DMSO. Rep-
licate T75 flasks for both treatments and controls were
performed (n = 4). Total RNA was isolated and analyzed
for CBFA2T3 isoform and SYK expression levels using
real-time RT-PCR. MDA-MB-231 cells were also treated
with the HDAC inhibiting agents trichostatin A (Sigma),
sodium butyrate (Sigma) and apicidin (Calbiochem).
Only trichostatin A elicited re-expression levels similar to
5-Aza-dC (data not shown).
Real-time methylation-specific PCR (MSP)
A sequencing amplicon was initially tested for bisulfite
PCR amplification and cloning bias by scoring percent
methylation frequencies of overlapping amplicons.
Bisulfite PCR bias was also tested by amplification on pro-
portional mixtures of hypo and hypermethylated bisulfite
treated DNA. This amplicon was PCR amplified and col-
umn purified from all samples. Second-round real-time
MSP was performed on the amplicon using internal for-
ward primers to detect for either unmethylated or methyl-
ated cytosines at the Sp1 site displaying high-frequency
cytosine methylation. The methylated and unmethylated
primer specificities were tested by real-time amplification
on serial dilutions of unmethylated and methylated
clones, respectively. Second-round amplicons were also
sequenced to ensure specificity. Second real-time MSP was
performed on a Rotor-Gene 2000 using internal forward
primers under standard 25 µl HotStar Taq conditions with
approximately 100 ρg of first-round cleaned amplicon
and 0.35X SYBR Green I. Amplifications were at 95°C for
10 min, 45 cycles at 94°C for 20 s, annealing temperature
for 30 s and 72°C for 30 s. Unknown unmethylated and
methylated cytosine levels were extrapolated at the Sp1
site from standard curve dilutions of internally PCR
amplified and column purified cloned amplicons origi-
nally sequenced and found to be representative of either
unmethylated (e.g. BT-483) or methylated (e.g. MDA-MB-
231) sequence. Unmethylated and methylated mlcl num-
bers were quantitated from all samples at the parameter
CT from standard curves with known mlcls/µl calculated
from the dilution mass in µg/µl ÷ M.W. of dsDNA clone
sequence (× 6.02 × 1017 mlcls/µmole). CBFA2T3B pro-
moter methylation levels were expressed as methylation
indices [mi = m/(m + u)] and ratios (u/m) [49,50].
Statistical analysis
CBFA2T3B promoter methylation index medians and
interquartile ranges were determined for each group of tis-
sue samples. Statistical comparisons between groups were
performed using the two-way Levene's test for Equality of
Variances, i.e. H0: median methylation index variances
are the same in each group; HA: median methylation
index variances are not the same in each group. Variances
in the median methylation indices between each group
were considered statistically significant when P ≤ .05. Cor-
relations between CBFA2T3B promoter methylation and
gene expression levels were determined by calculating a
Spearman's rank coefficient. All statistical analyses were
performed using GraphPad Prism Version 4.0.
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Additional material
Additional File 1
CBFA2T3 gene expression levels assayed using real-time RT-PCR The 
raw data CBFA2T3B expression levels and preliminary CBFA2T3A 
expression levels in breast tumor cell lines are shown. The y-axis represents 
the fluorescence detection scale and the x-axis represents the CT of ampli-
fication. The CBFA2T3 gene expresses at endogenously low levels and 
requires at least 500 ng of reverse transcribed total RNA to cDNA tem-
plate for reproducible detection. In contrast, the housekeeping genes such 
as CYPA require only 100 ng of template. When 500 ng is used, the 
CYPA expression levels are off the fluorescence scale. Note the CT values 
are below 35 cycles for the down-regulated cell lines such as MDA-MB-
231. This low-level of expression is undetectable by conventional RT-PCR. 
Moreover, because of this low endogenous expression the CBFA2T3 
mRNA could not be reliably detected using Northern Blots or RNase pro-
tection (pdf file).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-3-22-S1.pdf]
Additional File 2
CBFA2T3B promoter methylation levels examined using MSP The 
methylation levels in 24 breast tumor cell lines (labeled), 20 primary 
breast tumors (1T-20T), 20 normal breast counterparts (1N-20N) and 
24 normal whole blood samples (1–24) are shown. Four separate regions 
(1–4) spanning 1-kb of CBFA2T3B promoter sequence were amplified 
using primers to detect for either unmethylated or methylated cytosines 
(see Figure 1B for primer locations and Additional file 7 for primer 
sequences and annealing temperatures). The asterisks indicate the sam-
ples examined by bisulfite sequencing. Unmethylated (U) and methylated 
(M) band intensities were scored as high (black dot), low (gray dot) or 
negative (white dot). Low-level basal methylation defined by high 
unmethylated to low methylated band intensities was detected in all nor-
mal bloods in ≥ 2/4 regions. High methylation was also detected in 21% 
of bloods in region four. Samples were considered hypermethylated when 
high intensity bands amplified in all four regions or hypomethylated when 
no methylation was detected. Based on this, 21% of breast tumor cell lines 
were hypermethylated (e.g. MDA-MB-231 and MDA-MB-468), 16% 
hypomethylated (e.g. BT-483 and MDA-MB-361) and 63% displayed a 
combination of basal to high methylation. Primary breast tumor samples 
were complex. 57% displayed basal methylation in ≥ 2/4 regions, 14% 
displayed high methylation in ≥ 2/4 regions and 29% tested negative in 
≥ 3/4 regions. Normal breast counterpart samples were similar with 62% 
displaying basal methylation in ≥ 2/4 regions, 14% displaying high meth-
ylation in ≥ 2/4 regions and 24% testing negative in ≥ 3/4 regions. The 
detection of high-methylation in MCF-7 is due to spurious amplification 
events. Several overlapping primers spanning this region in this cell line 
were methylation negative (data not shown). This cell line is hypomethyl-
ated according to real-time MSP (pdf file).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-3-22-S2.pdf]
Additional File 3
CBFA2T3B promoter methylation levels assayed using second-round 
real-time MSP CBFA2T3B promoter methylation levels were assayed 
using second-round real-time MSP. The raw data methylation levels in 
normal whole blood samples and breast tumor cell lines are shown. The y-
axis represents the fluorescence detection scale and the x-axis represents 
the CT of amplification. Second round real-time MSP was performed on a 
bisulfite sequencing amplicon using internal forward primers to detect for 
either unmethylated (uF) or methylated (mF) cytosines at the Sp1 CpG 
sites shown in Figure 1C. The CT for methylated amplification in breast 
tumor cell lines was highly aberrant compared to normal blood samples. 
Note the late unmethylated CT obtained in MDA-MB-231 compared the 
early hypermethylated CT. In contrast, BT-483 shows an early unmethyl-
ated and late hypomethylated CT (pdf file).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-3-22-S3.pdf]
Additional File 4
CBFA2T3B promoter methylation melt curve analysis CBFA2T3B pro-
moter methylation melt curves were examined following second-round 
real-time MSP. Raw data melt curves of second round amplicons in nor-
mal blood samples and breast tumor cell lines are shown. Curves were cal-
culated from the negative derivative in fluorescence over temperature 
versus temperature (-dF/dTm versus Tm). Normal blood samples displayed 
consistent peak levels for both the unmethylated and methylated mlcls. In 
contrast, breast tumor cell lines displayed highly aberrant peak levels 
depicted by broad melt transitions and heterogeneous melt curves reflective 
of the aberrant concentration and composition of 5-methylcytosines (pdf 
file).
Click here for file
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Additional File 5
CBFA2T3B promoter methylation levels versus gene expression Meth-
ylation indices were calculated as methylated promoter mlcls per 104 cells 
for breast tumor cell lines with pre-determined 16q24.3 DNA mlcls per 
cell and plotted against CBFA2T3 mRNA mlcls per 104 cells. The y-axis 
represents methylation levels assayed using real-time MSP and the x-axis 
represents expression levels assayed using real-time RT-PCR. Both data 
sets are shown on a log scale. Each black circle represents a different breast 
tumor cell line. The asterisk marks the median methylation and median 
gene expression levels. The median methylation index of 0.02 (i.e. 2 mlcls 
or alleles methylated in 100) is calculated from the median methylation 
level of 450 methylated alleles per 104 cells divided by the number of 
unmethylated 'active' alleles in the 104 cells or 20,000 alleles, i.e. [450 ÷ 
(20,000 - 450) = 0.02]. The median gene expression index of 0.2 (i.e. 
20 mRNA mlcls expressed in 98 'active' alleles) is calculated from the 
median expression level of 4,500 mRNA mlcls per 104 cells divided by the 
number of unmethylated 'active' mlcls in the 104 cells, i.e. (4,500 ÷ 
19,550 = 0.2). This calculation equates to approximately 4–5 mRNA 
mlcls expressed per 10 cells and suggests that the CBFA2T3B gene is 
largely transcriptionally inert. The remaining active alleles may be trans-
factor dependent for expression. An inverse correlation between promoter 
methylation and expression levels per population of cells was established 
(r2 = 0.77; r = -0.9, P < .0001). In hypermethylated MDA-MB-231, 
approximately 17,000 promoter mlcls were methylated (i.e. mi = 0.85 as 
17,000 in 20,000 are methylated) and 4 mRNA mlcls expressed per 104 
cells. In hypomethylated BT-483, approximately 5 promoter mlcls were 
methylated (mi = 0.0002) and 120,000 (± 40,000) mRNA mlcls 
expressed per 104 cells. This elevated expression equates that 12 (± 4) 
mRNA mlcls per cell are expressed from an estimated four-promoter mlcls 
per cell (i.e. four-16q24.3 DNA mlcls per cell) or that one 'active' 
unmethylated CBFA2T3B promoter mlcl per cell transcribes 2–4 mRNA 
mlcls. From a methylation index of approximately 2% and greater, a large 
increase in y may lead to a small decrease in x. Under this condition, the 
relationship may be asymptotic. The regression equation y = 25,801 x-0.58 
(r2 = 0.7669) describes the methylation and expression relationship. 
When plotted as methylation index values the equation was y = 1.05 x-0.61 
(r2 = 0.7665) (pdf file).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
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Additional File 6
CBFA2T3B promoter methylation levels assayed using second-round 
real-time MSP The methylation levels in normal whole blood samples, 
normal breast counterparts, primary breast tumors and breast tumor cell 
lines were assayed at the Sp1 site shown in Figure 1C and plotted as abso-
lute methylation ratios (u/m). All samples are labeled corresponding in 
part to Additional file 2. The asterisks indicate the samples examined by 
bisulfite sequencing. The gray highlights indicate the normal blood and 
normal breast counterpart 'full' methylation ranges. Basal methylation 
ratios in normal bloods averaged 60:1 (cumulative mean) unmethylated 
to methylated CBFA2T3B promoter mlcls. This average coincided with 
conventional MSP band intensities of 100:1 based on pUC19 DNA/MspI 
marker concentrations (see Figure 3) and the median methylation index 
of 0.02 (i.e. 2 mlcls in 100 are methylated). Normal blood ratios ranged 
20:1 to 160:1 unmethylated to methylated mlcls. Normal breast counter-
parts were similar to normal bloods averaging 100:1 but with a larger 
range of 10:1 to 350:1. Relative to the normal samples, breast tumors dis-
played highly aberrant methylation ratios clearly resolved by second-round 
real-time MSP. 75% of breast tumor cell lines were aberrantly methylated 
outside the full range of normal blood basal methylation. 58% were out-
side the range of normal breast. Half of the aberrations were either hypo 
or hypermethylated relative to both normal blood and normal breast. Sim-
ilar to cell lines, 51% of primary breast tumors were aberrantly methylated 
relative to normal blood. 35% were aberrant relative to normal breast (i.e. 
24% were hypermethylated and 11% hypomethylated). Aberrant methyl-
ation ratios ranged from 1:10 in hypermethylated MDA-MB-231 to 
7,000:1 in hypomethylated BT-483 (pdf file).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-3-22-S6.pdf]
Additional File 7
Primers, probes and annealing temperatures used (pdf file).
Click here for file
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